Takeda Common Stock Shares Outstanding vs Other Stockholder Equity Analysis

TAK Stock

USD 13.31 0.08 0.60%

Takeda Pharmaceutical financial indicator trend analysis is much more than just breaking down Takeda Pharmaceutical prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Takeda Pharmaceutical is a good investment. Please check the relationship between Takeda Pharmaceutical Common Stock Shares Outstanding and its Other Stockholder Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Common Stock Shares Outstanding vs Other Stockholder Equity

Common Stock Shares Outstanding vs Other Stockholder Equity Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Takeda Pharmaceutical Common Stock Shares Outstanding account and Other Stockholder Equity. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Takeda Pharmaceutical's Common Stock Shares Outstanding and Other Stockholder Equity is -0.01. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Takeda Pharmaceutical Co, assuming nothing else is changed. The correlation between historical values of Takeda Pharmaceutical's Common Stock Shares Outstanding and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Takeda Pharmaceutical Co are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Common Stock Shares Outstanding i.e., Takeda Pharmaceutical's Common Stock Shares Outstanding and Other Stockholder Equity go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Other Stockholder Equity

Most indicators from Takeda Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Takeda Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

At this time, Takeda Pharmaceutical's Tax Provision is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 0.46 this year, although the value of Selling General Administrative will most likely fall to about 760.9 B.

	2021	2022	2023	2024 (projected)
Interest Expense	166.6B	169.7B	219.9B	230.8B
Depreciation And Amortization	591.5B	718.7B	728.0B	764.4B

Interest Expense Depreciation And Amortization

Takeda Pharmaceutical fundamental ratios Correlations

	Total Assets	Common Stock Shares Outstanding	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		-0.14	0.98	0.94	0.96	0.98	0.98	-0.08	0.98	-0.31	0.84	0.46	1.0	0.53	0.32	0.81	0.99	-0.58	0.98	0.98	0.9	0.95	0.99	0.9	0.91	0.5
Common Stock Shares Outstanding	-0.14		-0.01	-0.11	-0.07	-0.25	-0.29	-0.1	-0.03	-0.11	-0.43	0.16	-0.16	-0.48	0.08	0.05	-0.12	0.02	-0.04	-0.16	-0.41	-0.01	-0.05	-0.37	0.19	0.36
Short Long Term Debt Total	0.98	-0.01		0.89	0.96	0.92	0.93	-0.02	1.0	-0.34	0.75	0.49	0.98	0.42	0.33	0.85	0.98	-0.6	0.99	0.94	0.82	0.94	1.0	0.81	0.94	0.59
Other Current Liab	0.94	-0.11	0.89		0.94	0.94	0.94	-0.35	0.9	-0.34	0.91	0.4	0.94	0.48	0.24	0.67	0.92	-0.6	0.89	0.94	0.87	0.88	0.91	0.93	0.83	0.48
Total Current Liabilities	0.96	-0.07	0.96	0.94		0.92	0.93	-0.15	0.97	-0.33	0.82	0.38	0.96	0.44	0.2	0.77	0.95	-0.64	0.94	0.95	0.86	0.88	0.97	0.86	0.88	0.66
Total Stockholder Equity	0.98	-0.25	0.92	0.94	0.92		1.0	-0.18	0.93	-0.29	0.9	0.38	0.98	0.66	0.26	0.72	0.97	-0.54	0.92	0.99	0.95	0.91	0.93	0.97	0.83	0.4
Property Plant And Equipment Net	0.98	-0.29	0.93	0.94	0.93	1.0		-0.14	0.93	-0.31	0.9	0.38	0.98	0.65	0.25	0.74	0.97	-0.56	0.93	0.98	0.95	0.91	0.94	0.96	0.82	0.4
Current Deferred Revenue	-0.08	-0.1	-0.02	-0.35	-0.15	-0.18	-0.14		-0.05	0.14	-0.3	0.24	-0.09	-0.29	0.28	0.3	-0.05	0.14	0.04	-0.2	-0.16	-0.06	-0.01	-0.31	0.06	-0.25
Net Debt	0.98	-0.03	1.0	0.9	0.97	0.93	0.93	-0.05		-0.32	0.76	0.42	0.98	0.46	0.26	0.83	0.98	-0.59	0.99	0.95	0.85	0.93	0.99	0.83	0.92	0.61
Retained Earnings	-0.31	-0.11	-0.34	-0.34	-0.33	-0.29	-0.31	0.14	-0.32		-0.35	-0.33	-0.32	-0.21	-0.2	0.04	-0.38	0.44	-0.32	-0.32	-0.13	-0.45	-0.32	-0.31	-0.23	-0.15
Accounts Payable	0.84	-0.43	0.75	0.91	0.82	0.9	0.9	-0.3	0.76	-0.35		0.23	0.86	0.56	0.1	0.52	0.83	-0.5	0.75	0.85	0.88	0.77	0.78	0.95	0.61	0.21
Cash	0.46	0.16	0.49	0.4	0.38	0.38	0.38	0.24	0.42	-0.33	0.23		0.44	-0.1	0.93	0.48	0.49	-0.34	0.53	0.37	0.17	0.54	0.5	0.27	0.63	0.05
Non Current Assets Total	1.0	-0.16	0.98	0.94	0.96	0.98	0.98	-0.09	0.98	-0.32	0.86	0.44		0.54	0.29	0.8	0.99	-0.58	0.98	0.98	0.91	0.94	0.98	0.92	0.89	0.49
Non Currrent Assets Other	0.53	-0.48	0.42	0.48	0.44	0.66	0.65	-0.29	0.46	-0.21	0.56	-0.1	0.54		-0.11	0.13	0.52	-0.25	0.41	0.65	0.72	0.45	0.42	0.71	0.24	0.14
Cash And Short Term Investments	0.32	0.08	0.33	0.24	0.2	0.26	0.25	0.28	0.26	-0.2	0.1	0.93	0.29	-0.11		0.33	0.34	0.0	0.38	0.24	0.06	0.37	0.34	0.15	0.48	-0.11
Net Receivables	0.81	0.05	0.85	0.67	0.77	0.72	0.74	0.3	0.83	0.04	0.52	0.48	0.8	0.13	0.33		0.81	-0.42	0.87	0.72	0.68	0.77	0.86	0.58	0.9	0.42
Common Stock Total Equity	0.99	-0.12	0.98	0.92	0.95	0.97	0.97	-0.05	0.98	-0.38	0.83	0.49	0.99	0.52	0.34	0.81		-0.6	0.98	0.97	0.88	0.97	0.99	0.89	0.9	0.47
Short Term Investments	-0.58	0.02	-0.6	-0.6	-0.64	-0.54	-0.56	0.14	-0.59	0.44	-0.5	-0.34	-0.58	-0.25	0.0	-0.42	-0.6		-0.57	-0.56	-0.48	-0.62	-0.59	-0.52	-0.47	-0.47
Non Current Liabilities Total	0.98	-0.04	0.99	0.89	0.94	0.92	0.93	0.04	0.99	-0.32	0.75	0.53	0.98	0.41	0.38	0.87	0.98	-0.57		0.93	0.82	0.95	1.0	0.82	0.94	0.51
Inventory	0.98	-0.16	0.94	0.94	0.95	0.99	0.98	-0.2	0.95	-0.32	0.85	0.37	0.98	0.65	0.24	0.72	0.97	-0.56	0.93		0.93	0.92	0.95	0.94	0.85	0.5
Other Current Assets	0.9	-0.41	0.82	0.87	0.86	0.95	0.95	-0.16	0.85	-0.13	0.88	0.17	0.91	0.72	0.06	0.68	0.88	-0.48	0.82	0.93		0.8	0.84	0.96	0.7	0.35
Other Stockholder Equity	0.95	-0.01	0.94	0.88	0.88	0.91	0.91	-0.06	0.93	-0.45	0.77	0.54	0.94	0.45	0.37	0.77	0.97	-0.62	0.95	0.92	0.8		0.94	0.84	0.87	0.41
Total Liab	0.99	-0.05	1.0	0.91	0.97	0.93	0.94	-0.01	0.99	-0.32	0.78	0.5	0.98	0.42	0.34	0.86	0.99	-0.59	1.0	0.95	0.84	0.94		0.84	0.94	0.56
Property Plant And Equipment Gross	0.9	-0.37	0.81	0.93	0.86	0.97	0.96	-0.31	0.83	-0.31	0.95	0.27	0.92	0.71	0.15	0.58	0.89	-0.52	0.82	0.94	0.96	0.84	0.84		0.69	0.29
Total Current Assets	0.91	0.19	0.94	0.83	0.88	0.83	0.82	0.06	0.92	-0.23	0.61	0.63	0.89	0.24	0.48	0.9	0.9	-0.47	0.94	0.85	0.7	0.87	0.94	0.69		0.54
Short Term Debt	0.5	0.36	0.59	0.48	0.66	0.4	0.4	-0.25	0.61	-0.15	0.21	0.05	0.49	0.14	-0.11	0.42	0.47	-0.47	0.51	0.5	0.35	0.41	0.56	0.29	0.54

Click cells to compare fundamentals

Takeda Pharmaceutical Account Relationship Matchups

Takeda Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	12.8T	12.9T	13.2T	14.0T	15.1T	15.9T
Common Stock Shares Outstanding	1.6B	1.6B	1.6B	1.6B	1.6B	1.3B
Short Long Term Debt Total	5.1T	4.6T	4.3T	4.4T	4.8T	5.1T
Other Current Liab	682.3B	790.7B	1.4T	1.5T	1.3T	1.4T
Total Current Liabilities	2.2T	1.8T	2.1T	2.5T	2.3T	2.4T
Total Stockholder Equity	4.7T	5.2T	5.7T	6.4T	7.3T	7.6T
Property Plant And Equipment Net	1.4T	1.5T	1.6T	1.7T	2.0T	2.1T
Current Deferred Revenue	119.5B	588.0B	616.5B	109.9B	126.4B	120.1B
Net Debt	4.5T	3.7T	3.5T	3.8T	4.4T	4.6T
Retained Earnings	1.4T	1.5T	1.5T	1.5T	1.4T	1.4T
Accounts Payable	318.8B	343.8B	516.3B	649.2B	547.5B	574.9B
Cash	637.6B	966.2B	849.7B	533.5B	457.8B	587.6B
Non Current Assets Total	10.4T	10.2T	10.6T	11.6T	12.6T	13.2T
Non Currrent Assets Other	103.8B	100.3B	82.6B	63.3B	4.3T	4.5T
Cash And Short Term Investments	653.4B	1.0T	875B	553.7B	457.8B	722.1B
Net Receivables	784.9B	812.7B	724.4B	681.7B	697.6B	549.4B
Common Stock Total Equity	168.7B	1.6T	1.7T	1.7T	1.9T	2.0T
Short Term Investments	15.8B	36.6B	25.3B	20.2B	18.2B	17.2B
Liabilities And Stockholders Equity	12.8T	12.9T	13.2T	14.0T	15.1T	15.9T
Non Current Liabilities Total	5.9T	6.0T	5.3T	5.1T	5.5T	5.8T
Inventory	759.6B	753.9B	853.2B	986.5B	1.2T	1.3T
Other Current Assets	114.2B	122.8B	141.1B	160.9B	193.3B	203.0B
Other Stockholder Equity	1.6T	1.6T	1.6T	1.6T	1.7T	1.8T
Total Liab	8.1T	7.7T	7.5T	7.6T	7.8T	8.2T
Property Plant And Equipment Gross	1.4T	1.5T	2.5T	2.7T	3.1T	3.3T
Total Current Assets	2.5T	2.7T	2.6T	2.4T	2.6T	2.0T
Accumulated Other Comprehensive Income	92.6B	366.1B	934.2B	1.5T	2.5T	2.6T
Short Term Debt	586.8B	22.2B	204.0B	339.6B	367.3B	385.6B
Common Stock	1.7T	1.7T	1.7T	1.7T	1.7T	1.8T
Good Will	4.0T	4.0T	4.4T	4.8T	5.4T	5.7T
Intangible Assets	4.2T	3.9T	3.8T	4.3T	4.9T	5.2T
Other Assets	10.4T	454.1B	678.7B	429.3B	493.7B	469.0B
Other Liab	1.1T	831.0B	1.2T	544.1B	625.7B	713.1B
Net Tangible Assets	(3.8T)	(3.5T)	(2.8T)	(2.5T)	(2.3T)	(2.4T)
Long Term Debt	4.5T	4.6T	4.1T	4.0T	4.6T	2.9T
Long Term Investments	369.5B	348.4B	330.1B	378.9B	435.7B	286.4B
Short Long Term Debt	586.8B	22.2B	204.0B	339.6B	390.5B	328.0B
Treasury Stock	(74.4B)	(57.1B)	(87.5B)	(59.6B)	(53.6B)	(56.3B)
Property Plant Equipment	1.4T	1.5T	1.6T	1.7T	1.9T	1.1T
Long Term Debt Total	4.5T	4.6T	4.1T	4.0T	4.6T	3.3T

Takeda Pharmaceutical Investors Sentiment

The influence of Takeda Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Takeda. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Takeda Pharmaceutical's public news can be used to forecast risks associated with an investment in Takeda. The trend in average sentiment can be used to explain how an investor holding Takeda can time the market purely based on public headlines and social activities around Takeda Pharmaceutical Co. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Takeda Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Takeda Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Takeda Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Takeda Pharmaceutical.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Takeda Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Takeda Pharmaceutical's short interest history, or implied volatility extrapolated from Takeda Pharmaceutical options trading.

Currently Active Assets on Macroaxis

F	Ford Motor
CRM	Salesforce
F	Ford Motor
BAC	Bank of America
MSFT	Microsoft

When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:

How To Invest In Takeda

Details

Is Takeda Stock a good investment?

Details

What is Takeda Pharmaceutical's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

Note that the Takeda Pharmaceutical information on this page should be used as a complementary analysis to other Takeda Pharmaceutical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for Takeda Stock analysis

When running Takeda Pharmaceutical's price analysis, check to measure Takeda Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Takeda Pharmaceutical is operating at the current time. Most of Takeda Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Takeda Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Takeda Pharmaceutical's price. Additionally, you may evaluate how the addition of Takeda Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

Is Takeda Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.12)

Dividend Share

188

Earnings Share

0.29

Revenue Per Share

1.4 K

Quarterly Revenue Growth

0.099

The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Takeda Common Stock Shares Outstanding vs Other Stockholder Equity Analysis

Common Stock Shares Outstanding vs Other Stockholder Equity

Common Stock Shares Outstanding vs Other Stockholder Equity Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Other Stockholder Equity

Takeda Pharmaceutical fundamental ratios Correlations

Takeda Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Takeda Pharmaceutical fundamental ratios Accounts

Takeda Pharmaceutical Investors Sentiment

Currently Active Assets on Macroaxis

Complementary Tools for Takeda Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Net Debt	+ 1.0	Short Long Term Debt Total
Total Liab	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Net	+ 1.0	Total Stockholder Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock Total Equity	+ 0.99	Total Assets

Short Term Investments	- 0.64	Total Current Liabilities
Other Stockholder Equity	- 0.62	Short Term Investments
Short Term Investments	- 0.6	Common Stock Total Equity
Short Term Investments	- 0.6	Other Current Liab
Short Term Investments	- 0.6	Short Long Term Debt Total
Total Liab	- 0.59	Short Term Investments